Is Adamax a real research compound?
Not in the literature. Adamax was created and named by vendors; there are no published studies of the molecule itself, and even its identity is vendor-defined rather than established in any pharmacopeia.
Summary
Semax has a real (if narrow and Russian) research history and drug registration; Adamax is a vendor-invented modification with no published literature of any kind, borrowing all of its parent's credibility.
Key answers
What evidence transfers from Semax?
Nothing formally. Semax's Russian stroke and optic-nerve literature belongs to a defined molecule with defined trials. Claiming Adamax is a longer-acting Semax is a marketing sentence built on an adamantane group, not a tested property.
What is the identity situation?
Semax has registration history and named trials behind it; Adamax has product listings. The parent compound's ambiguity is ordinary gray-market risk, while the analog adds 'does this molecule exist as described' on top.
Comparison matrix
| Dimension | Semax | Adamax |
|---|---|---|
| Overall evidence grade | D | E |
| Evidence label | Limited human evidence | Evidence unclear |
| Regulatory status | Varies by product and jurisdiction | Varies by product and jurisdiction |
| Editorial confidence | Low confidence | Low confidence |
| Efficacy | 2/5 limited | 0/5 not mapped |
| Safety | 2/5 limited | 0/5 not mapped |
| Regulatory risk | 4/5 high | 4/5 high |
| Product quality risk | 4/5 high | 5/5 very high |
| Primary claim categories | Cognitive claims, Neurologic research, Nasal peptide claims, Route-comparison claims | Cognitive claims, Nootropic claims, Neurorecovery claims, Semax derivative claims |
Peptide summaries
2/5 efficacy
Semax
Semax can be described as a CNS-oriented peptide with limited route-specific human evidence, but subcutaneous superiority remains a clinic and forum claim rather than a demonstrated human route advantage.
Varies by product and jurisdiction
0/5 efficacyAdamax
Adamax is a Semax analogue people discuss for focus and neurorecovery, but its dose, duration, safety, and product-identity questions should stay separate from parent-Semax evidence.
Varies by product and jurisdiction
References
- 1.
PubMed. Effectiveness of Semax in acute period of hemispheric ischemic stroke 1997.
PMID:11517472 Accessed 2026-06-08.
Russian-language controlled clinical trial in acute hemispheric ischemic stroke; route and regimen context require direct-source verification before any protocol display.
- 2.
PubMed. Kinetics of Semax penetration into the brain and blood of rats after intranasal administration 2006.
doi:10.1134/s1068162006010055 PMID:16523722 Accessed 2026-06-08.
Rat tracer study supporting intranasal brain/blood exposure plausibility; not direct human efficacy evidence.
- 3.
Other. Classification of Unscheduled Peptides 2025.
Accessed 2026-07-02.
New Zealand Medsafe submission identifying Adamax and Semax as ACTH analogues marketed as cognitive enhancers.